Epidermal growth factor receptor inhibitors: A moving target?

被引：14

作者：

Bates, SE ^{[1
]}

Fojo, T ^{[1
]}

机构：

[1] NCI, Ctr Canc Res, Bethesda, MD 20892 USA

来源：

CLINICAL CANCER RESEARCH | 2005年 / 11卷 / 20期

关键词：

D O I：

10.1158/1078-0432.CCR-05-1845

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：7203 / 7205

页数：3

共 33 条

[1] An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors [J].

Amador, ML ;

Oppenheimer, D ;

Perea, S ;

Maitra, A ;

Cusati, G ;

Iacobuzio-Donahue, C ;

Baker, SD ;

Ashfaq, R ;

Takimoto, C ;

Forastiere, A ;

Hidalgo, M .

CANCER RESEARCH, 2004, 64 (24) :9139-9143

[2] Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer [J].

Baselga, J ;

Albanell, J ;

Ruiz, A ;

Lluch, A ;

Gascón, P ;

Guillém, V ;

González, S ;

Sauleda, S ;

Marimón, I ;

Tabernero, JM ;

Koehler, MT ;

Rojo, F .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) :5323-5333

[3] Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J].

Baselga, J ;

Rischin, D ;

Ranson, M ;

Calvert, H ;

Raymond, E ;

Kieback, DG ;

Kaye, SB ;

Gianni, L ;

Harris, A ;

Bjork, T ;

Averbuch, SD ;

Feyereislova, A ;

Swaisland, H ;

Rojo, F ;

Albanell, J .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4292-4302

[4] Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family [J].

Bishop, PC ;

Myers, T ;

Robey, R ;

Fry, DW ;

Liu, ET ;

Blagosklonny, MV ;

Bates, SE .

ONCOGENE, 2002, 21 (01) :119-127

[5]

Buerger H, 2000, CANCER RES, V60, P854

[6] Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer [J].

Cappuzzo, F ;

Hirsch, FR ;

Rossi, E ;

Bartolini, S ;

Ceresoli, GL ;

Bemis, L ;

Haney, J ;

Witta, S ;

Danenberg, K ;

Domenichini, I ;

Ludovini, V ;

Magrini, E ;

Gregorc, V ;

Doglioni, C ;

Sidoni, A ;

Tonato, M ;

Franklin, WA ;

Crino, L ;

Bunn, PA ;

Varella-Garcia, M .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (09) :643-655

[7] FDA drug approval summary:: Erlotinib (Tarceva®) tablets [J].

Cohen, MH ;

Johnson, JR ;

Chen, YF ;

Sridhara, R ;

Pazdur, R .

ONCOLOGIST, 2005, 10 (07) :461-466

[8]

Daneshmand M, 2003, CLIN CANCER RES, V9, P2457

[9] A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma [J].

Dawson, NA ;

Guo, CF ;

Zak, R ;

Dorsey, B ;

Smoot, J ;

Wong, J ;

Hussain, A .

CLINICAL CANCER RESEARCH, 2004, 10 (23) :7812-7819

[10] Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1 [J].

Gebhardt, F ;

Zänker, KS ;

Brandt, B .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (19) :13176-13180

← 1 2 3 4 →